Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Marcus Keogh-Brown"'
Autor:
Carl A B Pearson, Fiammetta Bozzani, Simon R Procter, Nicholas G Davies, Maryam Huda, Henning Tarp Jensen, Marcus Keogh-Brown, Muhammad Khalid, Sedona Sweeney, Sergio Torres-Rueda, CHiL COVID-19 Working Group, CMMID COVID-19 Working Group, Rosalind M Eggo, Anna Vassall, Mark Jit
Publikováno v:
PLoS Medicine, Vol 19, Iss 5, p e1003990 (2022)
[This corrects the article DOI: 10.1371/journal.pmed.1003815.].
Externí odkaz:
https://doaj.org/article/dd35a2260148441f9ca5976df1fc714b
Autor:
Carl A B Pearson, Fiammetta Bozzani, Simon R Procter, Nicholas G Davies, Maryam Huda, Henning Tarp Jensen, Marcus Keogh-Brown, Muhammad Khalid, Sedona Sweeney, Sergio Torres-Rueda, CHiL COVID-19 Working Group, CMMID COVID-19 Working Group, Rosalind M Eggo, Anna Vassall, Mark Jit
Publikováno v:
PLoS Medicine, Vol 18, Iss 10, p e1003815 (2021)
BackgroundMultiple Coronavirus Disease 2019 (COVID-19) vaccines appear to be safe and efficacious, but only high-income countries have the resources to procure sufficient vaccine doses for most of their eligible populations. The World Health Organiza
Externí odkaz:
https://doaj.org/article/5483efc8283b4575ac5bc7800eb4b403
Autor:
Mark Jit, Mishal Khan, Matthew Quaife, Anna Vassall, Sedona Sweeney, Nichola Kitson, Theo Prudencio Juhani Capeding, Rosalind Eggo, Maryam Huda, Don Mudzengi, Nichola R Naylor, Simon Procter, Lela Serebryakova, Sergio Torres-Rueda, Veronica Vargas, Fiammetta Bozzani, Nicholas G Davies, Henning Jensen, Marcus Keogh-Brown, Nuru Saadi, Julia Shen
Publikováno v:
BMJ Global Health, Vol 6, Iss 5 (2021)
Background Policy makers need to be rapidly informed about the potential equity consequences of different COVID-19 strategies, alongside their broader health and economic impacts. While there are complex models to inform both potential health and mac
Externí odkaz:
https://doaj.org/article/12e2a1f1e9814ee099615b124bcc9b63
Publikováno v:
WIDER Working Paper.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f750ea3c7304fbceb62a48754bc60ca
https://doi.org/10.35188/unu-wider/2021/120-4
https://doi.org/10.35188/unu-wider/2021/120-4
Publikováno v:
WIDER Working Paper.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad3d13ba13b3e5211f1ff2466fd854ab
https://doi.org/10.35188/unu-wider/2021/119-8
https://doi.org/10.35188/unu-wider/2021/119-8
Publikováno v:
WIDER Working Paper.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c52497d4400027bbd1c6af85c6b67b6
https://doi.org/10.35188/unu-wider/2021/121-1
https://doi.org/10.35188/unu-wider/2021/121-1
Autor:
Laura J. V. Piddock, Richard Wise, Martin J. Blaser, David M. Livermore, Gail H. Cassell, Steven J. Projan, David Findlay, Kieran Hand, Frances Burke, Neil O. Fishman, Ragnar Norrby, Richard Bax, Stuart B. Levy, Roger Finch, Tony White, Chantal M. Morel, Otto Carrs, Robert Guidos, Michael J. Dawson, Marcus Keogh-Brown, Anthony R. White, Rick Davies, Ian Chopra, Glenn S. Tillotson, John H. Powers, Sarah Garner, Dominique L Monnet, Lloyd George Czaplewski
Publikováno v:
Journal of Antimicrobial Chemotherapy. 66:1948-1953
The original and successful business model of return on investment being sufficiently attractive to the pharmaceutical industry to encourage development of new antibacterial molecules and related diagnostics has been compromised by increasing develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d310dcbb5d76143cb6660bf6df04b695
https://doi.org/10.1093/jac/dkr260
https://doi.org/10.1093/jac/dkr260
Autor:
Michael J. Dawson, Martin J. Blaser, David Findlay, Neil Fishman, Stuart Levy, Sarah Garner, Rick Davies, Tony White, Marcus Keogh-Brown, Ian Chopra, Lloyd Czaplewski, John H. Powers, Steven J. Projan, Richard Wise, Roger Finch, Dominique Monnet, Ragnar Norrby, Laura J. V. Piddock, Kieran Hand, Robert Guidos, Chantal M. Morel, David M. Livermore, Frances Burke, Gail Cassell, Richard Bax, Otto Carrs, Glenn Tillotson
Publikováno v:
Journal of Antimicrobial Chemotherapy. 66:1945-1947
Regulatory agencies play a critical role in the licensing of new antimicrobial agents. To address the pivotal role played by regulatory agencies, particularly in the context of a paucity of new drugs active against bacteria resistant to currently ava
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d20d0a2474c53dc6cecad54797cf12e
https://doi.org/10.1093/jac/dkr259
https://doi.org/10.1093/jac/dkr259
Autor:
Roger Finch, David M. Livermore, Rick Davies, Frances Burke, Otto Carrs, Neil O. Fishman, John H. Powers, Richard Bax, Livermore David, David Findlay, Chantal M. Morel, Tony White, Gail H. Cassell, Richard Wise, Dominique L Monnet, Ragnar Norrby, Glenn S. Tillotson, Ian Chopra, Steven J. Projan, Robert Guidos, Stuart B. Levy, Marcus Keogh-Brown, Kieran Hand, Laura J. V. Piddock, Michael J. Dawson, Lloyd George Czaplewski, Martin J. Blaser, Sarah Garner
Publikováno v:
The Journal of antimicrobial chemotherapy. 66(9)
The dwindling supply of new antibiotics largely reflects regulatory and commercial challenges, but also a failure of discovery. In the 1990s the pharmaceutical industry abandoned its classical ways of seeking antibiotics and instead adopted a strateg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6abceb8bb2a5a10340a69d7305faa27
https://pubmed.ncbi.nlm.nih.gov/21700626
https://pubmed.ncbi.nlm.nih.gov/21700626